MDWD · MediWound Ltd.
AI read · Neutral
The AI's read
MediWound reports Q2 before the open with consensus EPS -$0.77 and revenue $2.59M, a -54.6% year-over-year drop. That kind of revenue collapse matters for a small-cap biotech with limited revenue runway and sentiment risk. The stock barely budged (+0.3%) after the preview and RSI is 44.7, so the market hasn't aggressively repriced yet. Price sits near the 52-week low, which caps obvious downside if results only match weak expectations. Our take leans bearish because the estimates show a sharp sales decline and continued negative earnings, which usually pressures sentiment in this group. Conviction 84%: the data is explicit, but asymmetry is muted by proximity to lows and tepid market reaction.